Last reviewed · How we verify
PrEP for participants without HIV
At a glance
| Generic name | PrEP for participants without HIV |
|---|---|
| Sponsor | HIV Prevention Trials Network |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit (NA)
- IPrEP Men's Study: Expanding the Reach of Prevention for Men in Kisumu, Kenya (EARLY_PHASE1)
- RESTORE Study R61 Phase: Recovery and Engagement for Stimulant Users on Re-entry (NA)
- Project SPEED - Streamlined Protocol for Early Engagement and Delivery of HIV Prevention With Long-acting Injectable Cabotegravir: A Nurse-driven Protocol (NA)
- Trauma Intervention to Optimize PrEP Among Women Who Inject Drugs (NA)
- Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection (PHASE3)
- The OPENS Trial: Offering Women PrEP (Aim 2) (NA)
- Mentor Moms+ Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PrEP for participants without HIV CI brief — competitive landscape report
- PrEP for participants without HIV updates RSS · CI watch RSS
- HIV Prevention Trials Network portfolio CI